YolTech Therapeutics

CMN Weekly (12 September 2025) - Your Weekly...

Some of the best links we picked up around the internet

CMN Weekly (5 September 2025) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (29 August 2025) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

CMN Weekly (1 August 2025) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

YOLT-203 Awarded EMA Orphan Drug Designation for...

YolTech Therapeutics announced earlier this week that the European Medicines Agency has granted Orphan Drug Designation to YOLT-203, its...

CMN Weekly (18 July 2025) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Clinical Update: YolTech's Base-Editing Therapy...

YolTech Therapeutics announced on Monday that the Chinese National Medical Products Administration has approved its IND application for YOLT-101 in...

CMN Weekly (6 June 2025) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

YolTech Therapeutics

Familial Hypercholesterolemia, (NCT06458010)
Sponsors:
RenJi Hospital

IND Enabling

Phase I

Phase II

Phase III

Type 1 Primary Hyperoxaluria, PH1, (NCT06511349)
Sponsors:
RenJi Hospital

IND Enabling

Phase I

Phase II

Phase III

Transthyretin Amyloidosis, ATTR, (NCT06539208)
Sponsors:
YolTech Therapeutics Co., Ltd

IND Enabling

Phase I

Phase II

Phase III

Familial Hypercholesterolemia, FH, (NCT06461702)
Sponsors:
YolTech Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Transthyretin Amyloidosis Cardiomyopathy, TTR, (NCT06082050)
Sponsors:
YolTech Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Search CRISPR Medicine